Premium
CD 133 allows elaborated discrimination and quantification of haematopoietic progenitor subsets in human haematopoietic stem cell transplants
Author(s) -
Radtke Stefan,
Görgens André,
Kordelas Lambros,
Schmidt Markus,
Kimmig Klaus R.,
Köninger Angela,
Horn Peter A.,
Giebel Bernd
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13362
Subject(s) - haematopoiesis , stem cell , progenitor cell , biology , immunology , progenitor , cancer research , microbiology and biotechnology
Summary The success of haematopoietic stem cell ( HSC ) transplantation largely depends on numbers of transplanted HSC s, which reside in the CD 34 + populations of bone marrow ( BM ), peripheral blood stem cells ( PBSC ) and umbilical cord blood ( UCB ). More specifically HSC s reside in the CD 38 low/− subpopulation, which cannot be objectively discriminated from mature CD 34 + CD 38 + progenitors. Thus, better marker combinations for the quantification of more primitive haematopoietic stem and progenitor cells in transplants are required. Recently, by combining CD 34 and CD 133 we could clearly distinguish CD 133 + CD 34 + multipotent and lympho‐myeloid from CD 133 low CD 34 + erythro‐myeloid progenitors in UCB samples. To qualify the assessment of CD 133 for routine quality control of adult HSC sources, we analysed the developmental potentials of CD 133 + and CD 133 low subpopulations in BM and PBSC . Similar to UCB , CD 133 expression objectively discriminated functionally distinct subpopulations in adult HSC sources. By implementing anti‐ CD 45 RA staining, which separates multipotent ( CD 133 + CD 34 + CD 45 RA − ) from lympho‐myeloid ( CD 133 + CD 34 + CD 45 RA + ) progenitor fractions, UCB was found to contain 2–3 times higher multipotent progenitor frequencies than BM and PBSC . To test for the consistency of CD 133 expression, we compared CD 133 + CD 34 + contents of 128 UCB samples with maternal and obstetrical factors and obtained similar correlations to related studies focusing on CD 34 + cell contents. In conclusion, implementation of anti‐ CD 133 staining into existing routine panels will improve the quality control analyses for HSC transplants.